New drug combo challenges standard leukemia treatment in major trial
NCT ID NCT06928376
Summary
This study is testing whether a new drug combination (venetoclax + CACAG) works better and is safer than the current standard chemotherapy ('3+7' regimen) for adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML). It will involve 160 participants who will be randomly assigned to receive one of the two treatment plans. The main goal is to see which treatment leads to more patients achieving remission after one course.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.